MSLN and glioblastoma: Based on our findings and evidence in literature, we are inclined to speculate while mesothelin overexpression may promote GBM pathology, that cellular and humoral immune responses directed against mesothelin this molecule may also trigger potent anti-tumor immune responses, presenting a novel antigenic target for immunodiagnosis and immunotherapy - with respect to antibody- and cell-based approaches for patients with GBM.